Lyell Immunopharma Inc. has issued 625,000 shares of its common stock to the securityholders of ImmPACT Bio USA Inc. following the achievement of certain clinical milestones. The transaction was conducted under a private placement and was exempt from registration under the Securities Act. The document does not provide the price of these shares.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lyell Immunopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-148897), on June 26, 2025, and is solely responsible for the information contained therein.